海正药业（英文）·anti-凯发官网首页

locally advanced or metastasized pancreatic cancer; locally advanced or metastatic non-small cell lung cancer.

for postmenopausal patients with early breast cancer adjuvant treatment, such patients estrogen or progesterone receptor positive or unknown receptor status . already received adjuvant tamoxifen therapy for 5 years of adjuvant therapy, postmenopausal women with early breast cancer patients , such patients estrogen or progesterone receptor positive or unknown receptor status . treatment of postmenopausal estrogen receptor-positive and progesterone receptor positive or unknown receptor status in patients with advanced breast cancer , these patients should be natural or artificial menopause induced menopause .

applicable to postmenopausal women with advanced breast cancer. of estrogen receptor -negative patients, if their tamoxifen showed positive clinical response, consider using this. it is suitable for postmenopausal women with hormone receptor -positive adjuvant treatment of early breast cancer. also could be applied for whom have received 2 to 3 years after he tamoxifen adjuvant treatment of postmenopausal female patient in the adjuvant treatment of hormone receptor positive early breast cancer.

treatment of malignant lymphoma, breast cancer , lung cancer , soft tissue sarcoma , esophagus cancer, stomach cancer , liver cancer , pancreatic cancer, melanoma , colorectal cancer , ovarian cancer, multiple myeloma, leukemia. intravesical help superficial bladder cancer, carcinoma in situ treatment and prevention of its recurrence after transurethral resection.

luteinizing hormone releasing hormone (lhrh) analogues or surgical orchiectomy joint also could be used in the treatment of advanced prostate cancer.